Takeda is committed to advancing care and providing continued support for the hemophilia A community.See howFor U.S. healthcare professionals only
Help your patients get started on ADYNOVATE
Takeda is proud to offer a variety of programs and resources to help assist your patients with hemophilia A.
This page provides information for your practice. The first tab, for HCPs and office staff, includes resources containing information about access, billing, and coding. The second tab, for nurses, contains tools designed to help support patients on their ADYNOVATE treatment journey.
ADYNOVATE is covered on over 99%* of Commercial and Medicaid health plans†
†Source: FINGERTIP FORMULARY®, as of 03/08/2023, is subject to change without notice by a health plan or state.
*Product coverage divided by total therapeutic category coverage, based on the Rx and Medicaid coverage using DRG medical lives.
ADYNOVATE Access: tools and resources
Download these helpful tools or contact Takeda Patient Services for assistance with accessing ADYNOVATE.
Sample letter of medical necessity
Download and use this letter as a template if a payer requires a statement of medical necessity for ADYNOVATE.
When you prescribe ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] for your patient, Takeda Patient Services is here for them. Our support specialists can address your patient’s questions and concerns and help get them the information they need. Call 1-888-229-8379 Monday - Friday 8:30AM - 8:00PM (ET).
Your local Takeda representative can synthesize coverage information by creating FINGERTIP FORMULARY® sheets that compare Takeda and non-Takeda product coverage across prescription, medical, and combined benefit programs from different health plans.
Healthcare providers are responsible for ensuring accurate and appropriate diagnostic coding to obtain reimbursement. Use the appropriate codes noted below or download the quick reference ADYNOVATE Billing and Coding Sheet.
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure. Do not report 96376 for a push performed within 30 minutes of a reported push of the same substance or drug; 96376 may be reported by facilities only)
CONTRAINDICATIONS: Prior anaphylactic reaction to ADYNOVATE, to the parent molecule (ADVATE® [Antihemophilic Factor (Recombinant)]), mouse or hamster protein, or excipients of ADYNOVATE (e.g. Tris, mannitol, trehalose, glutathione, and/or polysorbate 80).